By Chiru Murage
Transplant Genomics Inc. has acquired the rights to what could lead to clinical tests that would drastically improve the care of organ transplant recipients, extending their lives and reducing costs of healthcare. These tests would “use genomic markers of transplant graft status as part of a surveillance program to detect and respond to early signs of graft injury.” The tests will be used to monitor kidney transplant recipients, improving graft survival. They will address the danger of “subclinical actue organ rejection,” which is a significant cause of late graft loss. This minimally invasive blood test could predict organ rejection, and monitor the patient post-transplant to ensure that the transplant was effective.
Read the full article here.
